JP2025508075A5 - - Google Patents

Info

Publication number
JP2025508075A5
JP2025508075A5 JP2024553452A JP2024553452A JP2025508075A5 JP 2025508075 A5 JP2025508075 A5 JP 2025508075A5 JP 2024553452 A JP2024553452 A JP 2024553452A JP 2024553452 A JP2024553452 A JP 2024553452A JP 2025508075 A5 JP2025508075 A5 JP 2025508075A5
Authority
JP
Japan
Prior art keywords
heavy chain
constant region
amino acid
chain constant
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063821 external-priority patent/WO2023172890A2/en
Publication of JP2025508075A publication Critical patent/JP2025508075A/ja
Publication of JP2025508075A5 publication Critical patent/JP2025508075A5/ja
Pending legal-status Critical Current

Links

JP2024553452A 2022-03-07 2023-03-07 抗ilt2抗体及びその使用 Pending JP2025508075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268945P 2022-03-07 2022-03-07
US63/268,945 2022-03-07
PCT/US2023/063821 WO2023172890A2 (en) 2022-03-07 2023-03-07 Anti-ilt2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025508075A JP2025508075A (ja) 2025-03-21
JP2025508075A5 true JP2025508075A5 (cg-RX-API-DMAC7.html) 2026-03-12

Family

ID=87935886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553452A Pending JP2025508075A (ja) 2022-03-07 2023-03-07 抗ilt2抗体及びその使用

Country Status (10)

Country Link
US (1) US20250109201A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490196A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508075A (cg-RX-API-DMAC7.html)
KR (1) KR20250004950A (cg-RX-API-DMAC7.html)
CN (1) CN119365487A (cg-RX-API-DMAC7.html)
AU (1) AU2023231622A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254318A1 (cg-RX-API-DMAC7.html)
IL (1) IL315487A (cg-RX-API-DMAC7.html)
MX (1) MX2024010982A (cg-RX-API-DMAC7.html)
WO (1) WO2023172890A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025059304A2 (en) * 2023-09-12 2025-03-20 Agenus Inc. Methods of treating cancer using ilt2 antibodies and combination therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2541360A1 (en) * 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
MA47468A (fr) * 2017-02-09 2019-12-18 Bluefin Biomedicine Inc Anticorps anti-ilt3 et conjugués anticorps-médicament
CN113330033B (zh) * 2018-12-26 2024-11-29 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
MX2022001841A (es) * 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
JP2022553927A (ja) * 2019-10-14 2022-12-27 イナート・ファルマ・ソシエテ・アノニム Ilt-2阻害剤での癌の処置
US11634477B2 (en) * 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
CA3181197A1 (en) * 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Ilt-binding agents and methods of use thereof
JP2023537396A (ja) * 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ilt2に対する抗体およびその使用

Similar Documents

Publication Publication Date Title
US12331119B2 (en) Modified Fc fragment, antibody comprising same, and application thereof
AU2016274485B2 (en) LAG-3-binding molecules and methods of use thereof
KR102761886B1 (ko) Pd-1-결합 분자 및 그것의 사용 방법
JP2021525082A5 (cg-RX-API-DMAC7.html)
JP2018035138A5 (cg-RX-API-DMAC7.html)
JP2023528350A5 (cg-RX-API-DMAC7.html)
CA3020864A1 (en) Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
TWI814715B (zh) Adam9結合分子及使用其的方法
EP3880707A1 (en) HUMANIZED ANTI-SIRPa ANTIBODIES
US20230174648A1 (en) Sirp alpha and sirp beta 1 antibodies and uses thereof
JP2022545741A5 (cg-RX-API-DMAC7.html)
JP2021534797A5 (cg-RX-API-DMAC7.html)
JP2024515396A5 (cg-RX-API-DMAC7.html)
JP2023522730A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2025186381A (ja) Cd137結合分子及びその使用
JP2023523016A5 (cg-RX-API-DMAC7.html)
JP2025517737A5 (cg-RX-API-DMAC7.html)
CA3226306A1 (en) Novel multi-specific molecules
JP7192042B2 (ja) Lag‐3結合分子及びその使用方法
CA2986953C (en) Lag-3-binding molecules and methods of use thereof
NZ769634A (en) Anti-sirpa antibodies and methods of use thereof
WO2024088342A1 (en) Antibodies against cd24 and uses thereof
RU2023123926A (ru) Антитела к vista и их применение
NZ769634B2 (en) Anti-sirpa antibodies and methods of use thereof